An annual review of clinical trials for Alzheimer's disease highlights a growing number of active trials—and drugs—in the development pipeline and offers optimism for the global effort to find a cure.
As we approach 2026,late-stage programs across key therapeutic areas are poised to reshape treatment paradigms. Driven by novel mechanisms, first-in-class targets and more convenient administration ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results